📰 Olid News
Page 8 - Olid News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Olid. Real-time updates on events, politics, business and more.
May 31, 2023
Vancouver, British Columbia--(Newsfile Corp. - May 31, 2023) - Phenom Resources Corp. (TSXV: PHNM) (OTCQX: PHNMF) (FSE: 1PY0) ("Phenom" or the "Company") is pleased to announce that it has signed a Memorandum
May 31, 2023
MGI - Media and Games Invest SE: Solid Q1 2023, 4% Revenue Growth Driven by +8% from Advertising and -6% from Games, adj. EBITDA +9% Outgrowing Revenues due to Cost Reductions, Growth Guidance
May 31, 2023
Solid growth in subscriptions drives positive start to the year: Q1 2023 consolidated sales up 2.1% organically Key highlights Consolidated sales of €256 million, up +2.1%... | May 31, 2023
May 31, 2023
Solid growth in subscriptions drives positive start to the year: Q1 2023 consolidated sales up 2.1% organically Key highlights Consolidated sales of €256 million, up +2.1% organically1 and up +1.3%
May 30, 2023
Novaturas Group, the leader in the Baltic tourism market, recorded solid growth in the first quarter of this year, one of the best quarters in the company’s history. The diversified and broadest... | May 30, 2023
May 30, 2023
Helvetia Holding AG / Key word: Annual Results Helvetia presents a solid result for occupational benefits 30.05.2023 / 07:00 CET/CEST Media release Basel, 30 May... | May 30, 2023
May 30, 2023
Planegg/Martinsried, May 30, 2023. Medigene AG , an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will participate at the BIO... | May 30, 2023
May 29, 2023
MyJournals.org - Science - [ASAP] Solid Flow Mapping at the Bottom Section of a Pilot-Plant Scale Riser with the Help of a Radioactive Particle Tracking Technique (Industrial & Engineering Chemistry Research)
May 27, 2023
ISTANBUL--(BUSINESS WIRE)--Marti Technologies Inc. ("Marti" or the "Company"), Turkey's leading mobility app, today announced its financial results for the fourth quarter of 2022. The Company
May 26, 2023
Positive data support the potential of plixorafenib to induce deep and durable benefit for patients with BRAF-mutated (V600+) cancers In the V600+ population benefit was observed in both MAPK-inhibitor